Evolving definitions of remission in Crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 8, 2013, Pages 1645-1653

  Panaccione, Remo ^a   Colombel, Jean Frédéric ^b   Louis, Edouard ^c   Peyrin Biroulet, Laurent ^d   Sandborn, William J ^e  

^a UNIVERSITY OF CALGARY   (Canada)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Crohn's disease; Disease activity measurements; Mucosal healing; Serologic markers testing

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; CERTOLIZUMAB PEGOL; GLATIRAMER; INFLIXIMAB; METHOTREXATE;

ARTICLE; CLINICAL RESEARCH; CROHN DISEASE; DISEASE COURSE; HUMAN; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; PREVENTION STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; SEROLOGY;

BIOLOGICAL MARKERS; CROHN DISEASE; DISEASE PROGRESSION; HUMANS; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 84884571904     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318283a4b3     Document Type: Article

References (42)

1. Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis. 2010;69:638-643.
2. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior in Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.
3. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001;49:777-782.
4. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a populationbased cohort. Gastroenterology. 2010;139:1147-1155.
5. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010;105:289-297.
6. Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135: 1106-1113.
7. Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995;30:699-706.
8. Veloso FT, Ferreira JT, Barros L, et al. Clinical outcome of Crohn's disease: analysis according to Vienna classification and clinical activity. Inflamm Bowel Dis. 2001;7:306-313.
9. Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn's disease: what is the actual risk? Gut. 2011;60:1178-1181.
10. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut. 1994;35:231-235.
11. Pariente B, Cosnes J, Danese S, et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17: 1415-1422.
12. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443-1449.
13. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-269.
14. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637.
15. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-586.
16. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage: 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:914-921.
17. Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72:64-71.
18. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-1517.
19. Clerico M, Faggiano F, Palace J, et al. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis [review]. Cochrane Database Syst Rev. 2008;(2):CD005278.
20. The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786-1801.
21. Comi G, Martinelle V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (Pre CISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503-1511.
22. Lémann M, Colombel J-F, Grimaud JC, et al. Fecal calprotectin and high sensitivity C-reactive protein levels to predict mucosal healing in patients with Crohn's disease. A subanalysis of the STORI study. Presented at: 18th United European Gastroenterology Week; October 23-27, 2010; Barcelona, Spain.
23. Louis E, Mary J-Y, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63-70.
24. De Cruz P, Kamm MA, Prideaux L, et al. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2013;19:429-444.
25. Hébuterne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe Crohn's disease following treatment with certolizumab pegol. Gut. 2013;62:201-208.
26. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7:15-29.
27. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442.
28. Baert F, Moortgat L, van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010;138:463-468.
29. D'Haens GR, Noman M, Baert F, et al. Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology. 2002;122:A618.
30. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts longterm outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15:1295-1301.
31. Frøslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422.
32. Rimola J, Ordás I, Rodriguez S, et al. Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis. 2011;17:1759-1768.
33. Schreiber S, Reinisch W, Colombel J-F, et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: sub-analysis of CHARM. Gastroenterology. 2007;132:A147.
34. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574-1582.
35. Sandborn WJ, Panaccione R, Thakkar R, et al. Crohn's disease mucosal healing in adalimumab-treated patients is affected by disease duration: results from EXTEND. Gastroenterology. 2010;138:S164.
36. Peyrin-Biroulet L, Billioud V, D'Haens G, et al. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107: 1770-1776.
37. Colombel J, Rutgeerts P, Sandborn WJ, et al. Deep remission for adalimumabtreated patients with moderate to severe ileocolonic Crohn's disease: results from EXTEND. J Crohns Colitis. 2010;4:S11.
38. Colombel JF, Schreiber S, Rutgeerts P, et al. Effect of disease duration on 'deep remission': results from the EXTEND trial. Presented at: 18th United European Gastroenterology Week; October 23-27, 2010; Barcelona, Spain.
39. Colombel JF, Sandborn WJ, Louis E, et al. Identification of sub-groups of adalimumab-treated patients with Crohn's disease who experience high rates of deep remission [P069]. Presented at: 6th Congress of the European Crohn's and Colitis Organisation; February 24-26, 2011; Dublin, Ireland.
40. Colombel J, Rutgeerts P, Sandborn WJ, et al. Deep remission predicts long-term outcomes for adalimumab-treated patients with Crohn's disease: data from EXTEND. Gut. 2010:59:A80.
41. Sandborn W, Colombel J-F, Lomax K, et al. Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumabtreated patients with Crohn's disease: data from EXTEND. Am J Gastroenterol. 2010;105:S442-S443.
42. Colombel JF, Sandborn WJ, Louis E, et al. Economic impact of deep remission in adalimumab-treated patients with Crohn's disease: results from EXTEND [P070]. Presented at: 6th Congress of the European Crohn's and Colitis Organisation; February 24-26, 2011; Dublin, Ireland.